March 31 , 2017 (Fairfax, VA) – SoBran BioScience, a division of SoBran Inc., and a leading provider of pre-clinical GLP contract research announced the grand prize winner of the Innovation for Impact research prize sponsored in partnership with the Piedmont Triad Office of the North Carolina Biotechnology Center (NCBC). The Grand Prize was awarded last night at the 7th Biennial Triad BioNight hosted by the North Carolina Biotechnology Center.

The Innovation for Impact prize was established to celebrate the transformational science coming out of North Carolina. Researchers at universities and emerging companies in North Carolina were invited to answer, “How will your research heal, fuel or feed the world in the future?”

Grand Prize
Innovation for Impact Grand Prize Winner receiving a research study worth up to $10,000 and a cash prize of $1,000:

Shengmin Sang, Ph.D.
Associate professor and lead scientist in the Center for Excellence in Post-Harvest Technologies, North Carolina Agricultural and Technical State University (NC A&T)

Dr. Sang is researching a novel double pro-drug for preventing colorectal cancer, the second leading cause of cancer-related deaths in the United States.

Finalists
Innovation for Impact finalists each winning a $500 cash prize are:

Hye Won Kang, Ph.D.
Assistant research professor, family and consumer sciences, NC A&T

Anthony Kennedy, Ph.D.
Professor of analytical chemistry, East Carolina University

Perpetua Muganda, Ph.D.
Professor of biology, NCA&T

Nicholas Oberlies, Ph.D.
Professor of medicinal chemistry at the University of North Carolina Greensboro

“It was an honor to review all of the extraordinary submissions from university researchers and emerging companies in North Carolina,” observed Dr. Gregory Kelly, Vice President at SoBran. “The robust pool of contenders is a testament to the strong life sciences research community that has been fostered here in North Carolina.”

Judges from SoBran BioScience and the North Carolina Biotechnology Center chose the winner and finalists based on the level of innovation and the potential impact the research could have on healing, fueling or feeding the world.

About SoBran BioScience
SoBran BioScience has nearly 20 years of experience supporting complex preclinical research and drug discovery for government agencies, academic institutions, and biotechnology companies. SoBran is ISO 9001:2008 certified and leads the industry in designing and managing ethical animal care programs that meet the most demanding regulatory standards. For more information visit us at www.sobranbioscience.com.

Media Contact:
Soma’ Martin
SoBran Inc.
smartin@sobran-inc.com
703.352.9511 ex. 109